OncoMatch/Clinical Trials/NCT06270888
Hypofractionation (Radiation) Trial for Multiple Myeloma
Is NCT06270888 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies non-drug interventions for multiple myeloma.
This study if for people who have been diagnosed with multiple myeloma and their doctors are recommending radiation to help treat it. Typically, radiation consists of 2-3 weeks of external beam radiation therapy. Doctors leading this study would like to see if a shorter radiation course (i.e., hypofractionation) for pelvic radiation is safe for multiple myeloma. Because participants in this study will receive a shortened radiation course, each daily treatment dose that is delivered would be slightly higher than normal. This higher daily dose would be delivered because the study team would like to see if higher doses of radiation are as safe given over a shorter number of days compared to 2-3 weeks. The purpose of this study is to make sure that hypofractionation is safe and effective for individuals with multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Prior therapy
Must have received: standard of care treatment options
Have undergone appropriate standard of care treatment options (in the opinion of the treating investigator)
Cannot have received: concurrent anti-myeloma or systemic therapy
Exception: Participants may receive concurrent steroids.
Participants must not receive any concurrent anti-myeloma or systemic therapy of any form.
Cannot have received: prior radiation therapy to the area planning to be treated
Exception: defined as less than 10 percent of prior prescription dose
Participants must not have had prior radiation therapy (defined as less than 10 percent of prior prescription dose) to the area planning to be treated with radiation.
Cannot have received: cytotoxic chemotherapy
Participants who have had prior cytotoxic chemotherapy must not receive that therapy within 2 weeks of the initiation of radiation
Cannot have received: anti-cancer monoclonal antibody or other small molecules
Participants who have had prior anti-cancer monoclonal antibody (mAb) or other small molecules must not receive that therapy within 7 days of the initiation of radiation
Lab requirements
Blood counts
Adequate organ function, as defined by lab values that will be confirmed by the study doctor.
Kidney function
Adequate organ function, as defined by lab values that will be confirmed by the study doctor.
Liver function
Adequate organ function, as defined by lab values that will be confirmed by the study doctor.
Adequate organ function, as defined by lab values that will be confirmed by the study doctor.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of Chicago Comprehensive Cancer Center · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify